BridgeMD
New treatment option for Attention Deficit Hyperactivity Disorder
Official title Attention Deficit Hyperactivity Disorder
ClinicalTrials.gov ID: NCT06232226
What this study is testing
- What it's testing
- The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Patients aged over 18 years
- For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago
- For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed
- Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)
- For patients who can actually benefit from MPH: who have not yet started taking MPH
You likely can't join if
- Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making...
- Presenting difficulties in reading or writing the French language making data collection impossible
- Unable to commit to being available for the 2 visits planned as part of the cohort
- Under guardianship or legal protection
- Patients who have used psychoactive substances within 12 hours prior to their visit
See the full eligibility criteria
- Patients aged over 18 years
- For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago
- For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed
- Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)
- For patients who can actually benefit from MPH: who have not yet started taking MPH
- Social security affiliates
- Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible
- Presenting difficulties in reading or writing the French language making data collection impossible
- Unable to commit to being available for the 2 visits planned as part of the cohort
- Under guardianship or legal protection
- Patients who have used psychoactive substances within 12 hours prior to their visit
The study team makes the final eligibility decision.
Where it's taking place
- Nantes, Loire-Atlantique, France
- Brest, France
- Tours, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nantes, Loire-Atlantique, France; Brest, France; Tours, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.